Enzymatica AB: BioStock: Final study results - ColdZyme reduces illness duration and alleviates symptoms

An independent investigator-initiated study from the University of Kent demonstrates that Enzymatica's mouth spray ColdZyme reduces the duration of upper respiratory tract infections by up to five days in endurance athletes, enabling faster return to training. Additionally, ColdZyme alleviates symptoms and decreases the viral load of rhinovirus, the most common cause of a cold. Principal investigator Glen Davison shared insights on these results in an interview with BioStock.